V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 20215119 | 20081301 | 1.82 | 46.8 | Palliative (P) | 2018-09-08 | 2018-09-12 | Trial Unspecified | 1 | N | TRIAL | 101627672 |
| 20215121 | 20081302 | 1.73 | 75 | Palliative (P) | 2019-01-06 | 2019-01-22 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 100546650 |
| 20215122 | 20081303 | 1.75 | 78.45 | Palliative (P) | 2018-02-01 | 2018-02-06 | LANREOTIDE | N | N | LANREOTIDE | 100184777 |
| 20215123 | 20081304 | null | null | Adjuvant (A) | 2019-04-02 | 2019-04-23 | IMATINIB | 99 | N | IMATINIB | 100905695 |
| 20215125 | 20081305 | 1.59 | 79.3 | Curative (C) | 2018-04-02 | 2018-04-14 | Fluorouracil+Mitomycin+RT (Anal Ca) | 02 | Y | FLUOROURACIL + MITOMYCIN + RT | 100798125 |
| 20215126 | 20081306 | 1.63 | 58.3 | Curative (C) | 2018-03-17 | 2018-04-18 | Fluorouracil+Mitomycin+RT (Anal Ca) | null | null | FLUOROURACIL + MITOMYCIN + RT | 101584161 |
| 20215128 | 20081308 | 1.71 | 71.7 | null | 2017-03-18 | 2017-03-19 | CETUXIMAB + IRINOTECAN + MDG | 02 | null | CETUXIMAB + FLUOROURACIL + IRINOTECAN | 101541566 |
| 20215132 | 20081309 | 1.64 | 59.7 | null | 2017-11-20 | 2017-11-27 | LANREOTIDE | 02 | null | LANREOTIDE | 100111042 |
| 20215133 | 20081310 | 1.87 | 104.4 | Palliative (P) | 2017-12-29 | 2018-02-19 | Cape+Cisplatin+Trastuzumab Load | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 100549774 |
| 20215134 | 20081311 | 1.67 | 89 | Palliative (P) | 2018-06-04 | 2018-06-24 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 100202876 |
| 20215135 | 20081312 | 0 | null | 03 | 2019-02-20 | 2019-02-23 | LANREOTIDE | 02 | N | LANREOTIDE | 101361527 |
| 20215137 | 20081314 | 1.82 | 47.5 | 03 | 2020-03-09 | 2020-03-16 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | LANREOTIDE | 100128164 |
| 20215138 | 20081315 | 1.75 | 77.2 | Palliative (P) | 2016-07-11 | 2016-07-23 | HCX (Cape + Cisp + Tras) - Load | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 101099914 |
| 20215142 | 20081316 | 1.75 | 56.5 | Curative (C) | 2016-06-16 | 2016-07-05 | FLUOROURACIL + MITOMYCIN + RT | N | Y | FLUOROURACIL + MITOMYCIN + RT | 101810485 |
| 20215145 | 20081317 | null | null | Palliative (P) | 2017-06-26 | 2017-06-27 | Cape+Cisplatin+Trastuzumab Load | 02 | N | LANREOTIDE | 100366581 |
| 20215146 | 20081318 | null | 79.6 | Palliative (P) | 2017-02-16 | 2017-02-23 | LANREOTIDE | 02 | N | LANREOTIDE | 100094289 |
| 20215147 | 20081319 | 1.63 | 90 | Palliative (P) | 2018-11-30 | 2018-12-04 | HCX (Cape + Cisp + Tras) - Load | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 101412677 |
| 20215148 | 20081320 | 1.7 | 67.5 | Curative (C) | 2019-06-26 | 2019-06-26 | LANREOTIDE | 02 | N | LANREOTIDE | 101332863 |
| 20215149 | 20081321 | null | 69.2 | null | 2016-11-30 | 2016-12-08 | Trial Unspecified | Y | N | TRIAL | 100096977 |
| 20215150 | 20081322 | 1.66 | 71 | null | 2019-06-07 | 2019-06-15 | Cape+Cisplatin+Trastuzumab Load | 02 | null | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 100744363 |
| 20215151 | 20081323 | 0 | 50.2 | Disease modification (D) | 2017-01-20 | 2017-01-21 | LANREOTIDE | 02 | N | LANREOTIDE | 100828918 |
| 20215153 | 20081325 | 1.6 | 63 | Palliative (P) | 2018-07-16 | 2018-07-16 | Trial Unspecified | 1 | N | TRIAL | 101358098 |
| 20215154 | 20081326 | 1.6 | 63.5 | Curative (C) | 2017-08-27 | 2017-09-24 | Fluorouracil+Mitomycin+RT (Anal Ca) | 02 | Y | FLUOROURACIL + MITOMYCIN + RT | 100575560 |
| 20215156 | 20081327 | 1.7 | 0 | Neo-adjuvant (N) | 2019-05-03 | 2019-05-10 | Cape+Cisplatin+Trastuzumab Load | 02 | N | IMATINIB | 101497143 |
| 20215157 | 20081328 | 1.72 | 63.2 | Curative (C) | 2019-10-14 | 2019-10-26 | FLUOROURACIL + MITOMYCIN + RT | N | N | FLUOROURACIL + MITOMYCIN + RT | 101243063 |
| 20215159 | 20081330 | 1.7 | 63.9 | Palliative (P) | 2019-10-13 | 2019-10-13 | HCX (Cape + Cisp + Tras) - Load | 02 | N | LANREOTIDE | 101172881 |
| 20215160 | 20081331 | 1.8 | 83 | null | 2019-11-27 | 2019-12-13 | Fluorouracil+Mitomycin+RT (Anal Ca) | N | null | FLUOROURACIL + MITOMYCIN + RT | 101436141 |
| 20215162 | 20081332 | 1.67 | 78 | Curative (C) | 2018-12-04 | 2018-12-08 | FLUOROURACIL + MITOMYCIN + RT | N | Y | FLUOROURACIL + MITOMYCIN + RT | 101419907 |
| 20215163 | 20081333 | 1.67 | 88 | Curative (C) | 2019-08-06 | 2019-08-16 | FLUOROURACIL + MITOMYCIN + RT | N | N | FLUOROURACIL + MITOMYCIN + RT | 100398168 |
| 20215164 | 20081334 | 1.7 | 67.7 | Neo-adjuvant (N) | 2016-11-07 | 2016-12-03 | Cetuximab + FLUOROURACIL + FOLINIC ACID + IRINOTECAN | 02 | N | CETUXIMAB + FLUOROURACIL + IRINOTECAN | 100426562 |
| 20215165 | 20081335 | null | null | Palliative (P) | 2020-07-26 | 2020-07-27 | LANREOTIDE | 02 | N | LANREOTIDE | 100187047 |
| 20215166 | 20081336 | 1.75 | 84.1 | Palliative (P) | 2019-06-14 | 2019-06-14 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 101788033 |
| 20215167 | 20081337 | 1.73 | 95.6 | Curative (C) | 2018-07-07 | 2018-07-07 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | Y | FLUOROURACIL + MITOMYCIN + RT | 100416776 |
| 20215168 | 20081338 | 1.68 | 106 | null | 2016-11-21 | 2016-11-21 | LANREOTIDE | 02 | N | LANREOTIDE | 100614632 |
| 20215169 | 20081339 | 1.65 | 97.2 | null | 2017-02-07 | 2017-02-14 | Trial Unspecified | 01 | null | TRIAL | 100785299 |
| 20215170 | 20081340 | null | 82 | Palliative (P) | 2021-06-24 | 2021-07-22 | LANREOTIDE | 02 | N | LANREOTIDE | 101532868 |
| 20215173 | 20081341 | 1.7 | 70 | Curative (C) | 2019-01-04 | 2019-01-15 | IMATINIB | 02 | N | IMATINIB | 100046336 |
| 20215174 | 20081342 | 1.59 | 81.9 | Palliative (P) | 2017-07-14 | 2017-07-20 | Trial Unspecified | 01 | N | TRIAL | 101756530 |
| 20215175 | 20081343 | 1.82 | 114 | Palliative (P) | 2017-06-19 | 2017-07-09 | HCX | 02 | N | TRIAL | 101254915 |
| 20215176 | 20081344 | 1.71 | 80 | Curative (C) | 2019-09-19 | 2019-10-03 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | Y | TRIAL | 101713117 |
| 20215177 | 20081345 | 1.76 | 42.1 | null | 2017-07-03 | 2017-07-12 | IMATINIB | 02 | null | IMATINIB | 100625680 |
| 20215178 | 20081346 | 1.84 | 69.9 | Palliative (P) | 2018-04-21 | 2018-05-19 | LANREOTIDE | N | N | LANREOTIDE | 101198769 |
| 20215179 | 20081347 | 1.74 | 122.9 | Palliative (P) | 2017-05-14 | 2017-05-21 | Cape+Cisplatin+Trastuzumab Load | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 101663089 |
| 20215180 | 20081348 | 1.6 | 65.5 | Palliative (P) | 2019-06-12 | 2019-06-12 | Imatinib 400mg | 02 | N | IMATINIB | 100566834 |
| 20215181 | 20081349 | 1.82 | null | Palliative (P) | 2018-06-08 | 2018-06-08 | Trial Unspecified | 01 | N | TRIAL | 101462301 |
| 20215182 | 20081350 | 1.78 | 51 | Adjuvant (A) | 2018-02-03 | 2018-02-03 | IMATINIB | 02 | N | IMATINIB | 101244595 |
| 20215183 | 20081351 | 0 | 71 | 03 | 2018-05-15 | 2018-05-15 | Imatinib 400mg | 02 | N | IMATINIB | 101356614 |
| 20215184 | 20081352 | null | 77.8 | null | 2016-10-30 | 2016-11-03 | LANREOTIDE | 02 | null | LANREOTIDE | 101088985 |
| 20215185 | 20081353 | 1.73 | 0 | Adjuvant (A) | 2015-07-05 | 2015-07-15 | Imatinib 400mg | 02 | N | IMATINIB | 101370725 |
| 20215186 | 20081354 | 1.57 | 93 | Palliative (P) | 2018-08-30 | 2018-08-30 | Cape+Cisplatin+Trastuzumab Load | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 100741075 |